Primary Salivary Gland-Type Tumors of the Lung and Trachea
Conditions
Interventions
None listed
Sponsors
North East Japan Study Group (NEJSG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be included in the study; 1 Cases pathologically confirmed as salivary gland-type tumors through histological diagnosis. 2 Cases with clinical stage IIIA or higher that are deemed unresectable by curative surgical intervention, or cases of recurrence following surgical resection or definitive (chemo)radiotherapy. 3 Cases diagnosed as recurrent or advanced stage between January 1, 1981, and December 31, 2023.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded from the study; 1 Cases with a primary lesion originating in organs other than the lung or trachea. 2 Cases deemed inappropriate for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For all cases; Molecular biological investigations (driver gene mutations, PD-L1 expression) For cases receiving drug therapy; Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| For all cases; Overall survival For cases receiving drug therapy; Objective response rate, Disease control rate, and safety Treatment details; Local treatments (surgical treatment, radiotherapy, stent placement, interventional treatments, etc.), Drug therapies (chemotherapy, molecular targeted therapies, immune checkpoint inhibitors, etc.), Best supportive care | — |
Countries
Japan
Contacts
Public ContactShunichi Kataoka
Juntendo University Graduate School of Medicine Department of Respiratory Medicine
Outcome results
None listed